MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
This article was originally published in The Pink Sheet Daily
Executive Summary
Global players need to consider offering assistance in China, where most patients pay nearly 50 percent of their medical expenses out of pocket, and most simply cannot afford brand name innovative oncology drugs.